Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P)

被引：0
|
作者：
Birrer, Michael J.
Bondarenko, Igor
Tjulandin, Sergei
Vergote, Ignace
Cibula, David
Ray-Coquard, Isabelle
Colombo, Nicoletta
Allard, Aurore
Oprea, Corina
Rey, Augustin A.
Sessa, Cristiana
Pujade-Lauraine, Eric
机构：
[1] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA
[2] Dnipropetrovsk Med Acad, Dnepropetrovsk, Ukraine
[3] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[6] Ctr Leon Berard, F-69373 Lyon, France
[7] Ist Europeo Oncol, Milan, Italy
[8] Sanofi, Chilly Mazarin, France
[9] Sanofi, Vitry Sur Seine, France
[10] Ist Oncol Svizzera Italiana, Bellinzona, Switzerland
[11] Hop Hotel Dieu, F-75181 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PHASE 2, RANDOMIZED CONTROLLED STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATIN VERSUS GEMCITABINE AND CARBOPLATIN IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (GOTIC003/INTERGROUP STUDY)
    Fujiwara, H.
    Ushijima, K.
    Nagao, S.
    Takei, Y.
    Shimada, M.
    Takano, M.
    Yoshino, K.
    Kawano, Y.
    Hirashima, Y.
    Nagase, S.
    Nishio, S.
    Nishikawa, T.
    Ito, K.
    Shoji, T.
    Kimura, E.
    Takano, T.
    Sugiyama, T.
    Kigawa, J.
    Fujiwara, K.
    Suzuki, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 48 - 48
  • [32] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    S McMeekin
    R Patel
    C Verschraegen
    P Celano
    J Burke
    S Plaxe
    P Ghatage
    M Giurescu
    C Stredder
    Y Wang
    T Schmelter
    British Journal of Cancer, 2012, 106 : 70 - 76
  • [33] PHASE I/II STUDY OF SAGOPILONE (ZK-EPO) PLUS CARBOPLATIN IN WOMEN WITH RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J.
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 211 - 211
  • [34] Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    McMeekin, S.
    Patel, R.
    Verschraegen, C.
    Celano, P.
    Burke, J., II
    Plaxe, S.
    Ghatage, P.
    Giurescu, M.
    Stredder, C.
    Wang, Y.
    Schmelter, T.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 70 - 76
  • [35] A phase II, non-randomized study of abraxane plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer: Evaluation of side effects and tolerability
    Al Housseini, A.
    Daugherty, P.
    Sofidiya, M.
    Burrell, M.
    Boverie, J.
    Benigno, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    Pujade-Lauraine, Eric
    Wagner, Uwe
    Aavall-Lundqvist, Elisabeth
    Gebski, Val
    Heywood, Mark
    Vasey, Paul A.
    Volgger, Birgit
    Vergote, Ignace
    Pignata, Sandro
    Ferrero, Annamaria
    Sehouli, Jalid
    Lortholary, Alain
    Kristensen, Gunnar
    Jackisch, Christian
    Joly, Florence
    Brown, Chris
    Le Fur, Nathalie
    du Bois, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3323 - 3329
  • [37] A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients
    Vasey, P.
    Largillier, R.
    Gropp, M.
    Gebski, V.
    Sandvei, R.
    Elit, L.
    Angleitner-Boubezinek, L.
    Reed, N.
    Pignata, S.
    Ferrero, A. M.
    EJC SUPPLEMENTS, 2009, 7 (03): : 11 - 11
  • [38] Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
    Ledermann, J. A.
    Harter, P.
    Gourley, C.
    Friedlander, M.
    Vergote, I. B.
    Rustin, G. J. S.
    Scott, C.
    Meier, W.
    Shapira-Frommer, R.
    Safra, T.
    Matei, D.
    Macpherson, E.
    Watkins, C.
    Carmichael, J.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer
    Ferrandina, G
    Ludovisi, M
    Dagostino, G
    Lorusso, D
    Naldini, A
    Testa, AC
    Paris, I
    Gallotta, V
    Pozzo, C
    Scambia, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 468S - 468S
  • [40] Phase 1 and 2 Study of Carboplatin and Pralatrexate in Patients With Recurrent, Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    del Carmen, Marcela G.
    Supko, Jeff G.
    Horick, Nora K.
    Rauh-Hain, J. Alejandro
    Clark, Rachel M.
    Campos, Susana M.
    Krasner, Carolyn N.
    Atkinson, Tina
    Birrer, Michael J.
    CANCER, 2016, 122 (21) : 3297 - 3306
12345